BR, They couldn’t recruit patients inFSGS because of the surging covid but their initial trial was a success. For DES, the fared better than Restasis in efficacy but did not improve in the discomfort side effect. If they ever go GIA, I bet they will put this first priority.
News 
Market Data 
Discover 
AI
